Try our Advanced Search for more refined results
Life Sciences - September, 2019
356 articles
- Sterigenics Says It Will Not Pursue Reopening Of Ill. Facility
- Abbott Worker's $9M Age-Bias Verdict Slashed To $1.1M
- Oregon Health Agency Floats Vaping Ban To Governor
- Fed. Circ. Judge Slams Amgen Patent's 'Utter Lack Of Clarity'
- FDA, DEA Collaborate On Warnings Over Opioid Sales
- DOJ Wins Bids To End FCA Suits Targeting Eli Lilly, Bayer
- Canada Urged To Regulate CBD As Natural Health Supplement
- AstraZeneca Hit With Another Seroquel XR Pay-For-Delay Suit
- Locke Lord Adds Jenner & Block IP Partner In Chicago
- Fed. Circ. Is Sanctioning Government Theft, Celgene Warns
- PTAB Cuts Down Two More Allergan Restasis Patents
- WTO Dispute Roundup: Members Gird For Appellate Freeze
- Glumetza Makers Slapped With 2 New Suits Over Price Hikes
- Ex-Shkreli Employee's Expanded $1.3M Fraud Suit Lives On
- Purdue's $38M Bonus Plan In Ch. 11 Draws Watchdog's Ire
- FTC Taking A Closer Look At $63B AbbVie-Allergan Deal
- Michigan E-Cig Ban Withstands Early Challenge
- CBD Cos. Lied About Dosages, Proposed Class Action Says
- Opioid Negotiation Class May Be Organic Procedure Evolution
- Cooley To Steer Vir Biotechnology's $150M IPO
- J&J Beats Investor's Suit Over Talc-Cancer Link
- Ex-Sanofi Employee Says Doctor Program Was For Kickbacks
- True Wellness Requires A Deeper Look At Atty Profession
- Three Firms Steer Sobi's $915M Dova Pharma Buy
- NY Rep. Collins Resigns, Plans Insider Trading Guilty Plea
- 35 Charged In $2.1B Telehealth Gene Test Fraud
- Walgreens, Vision Direct Ink $12M Contact Lens Antitrust Deal
- 2 Classes Certified In Suboxone Product-Hop Suit
- Antitrust Case Against IQVIA Will Join Larger Fight In NJ
- J&J Hit With $40M Verdict In Calif. Talc Cancer Trial
- Sanofi Beats First Bellwether In Chemo Drug Hair Loss MDL
- High Court Told Not To Review Lilly's $20M Cialis Patent Loss
- Abbott Gets Win In 20-Year-Old Age Bias Suit OK'd
- Washington To Ban Flavored Vape Products, Including THC
- Eye on ERISA: Q&A With McDermott's Ted Becker
- Keep Med Supply Pricing Suit Buried, Becton Urges 7th Circ.
- King & Spalding Directs $925M Gatan Sale To Ametek
- Invisalign Maker Slips Suit Over Clear Aligner Market, For Now
- 13 Firms To Steer 6-IPO Week Dominated By Biotechs
- Dispensary Chain Ends 2-State License Fight With Pot Shop
- Sequoia Ruling Dodges Debate Over Fund Docs As Contracts
- Vaping Illnesses Tied To THC Cartridges, CDC Says
- Robbins Geller To Lead Reckitt Stock-Drop Suit
- Pursuing Wellness
- Mylan Inks $30M SEC Deal After Not Disclosing EpiPen Probe
- Insurer Must Cover Wholesaler's $3.5M W.Va. 'Pill Mill' Deal
- Minn. AG Defends Insulin Suit Against Sanofi, Novo, Lilly
- J&J Launches Appeal Of $572M Okla. Opioid Judgment
- Avanir To Pay $108M Over Nuedexta Drug Kickback Scheme
- Vaping Industry Group Sues To Block NY's Flavored E-Cig Ban
- 'Negotiation Class' In Opioid MDL Is Unlawful, 6th Circ. Told
- Teva Can't Escape Investors' Price-Fixing Claims, Judge Says
- Two Essure Users Fight Uphill To Keep Injury Claims Alive
- Health Co. Hits Rival With TM Suit, Cites Emoji-Ridden Posts
- What To Do When A Private Equity Firm Wants Your Business
- FDA Issues Rare 2nd Warning Over Sleep Drug Promos
- Rival Can't Shake AngioDynamics' $145M Racketeering Suit
- How BigLaw Is Adapting To Plaintiff-Side Litigation
- Calif. Tells Judge J&J Must Pay $800M For Mesh Marketing
- Unpacking The Latest ITC Trends: Part 2
- Opioid MDL Judge Won't Withdraw Over Bias Charge
- Battle Lines Drawn For Opioid MDL's Bellwether Trial
- Judge Blocks Talk Of J&J Mesh Sales Revenue In Calif. Trial
- Gov't Claimants Want Insys Bankruptcy Converted To Ch. 7
- J&J, Colgate Can't Ditch $10M Award In Calif. Talc Trial
- DOJ Targets Telehealth Fraud Tied To Genetic Testing
- NantHealth Urges Chancery To Boot Research Deal Suit
- FDA Acting Head Says E-Cig Policy To Be Final Soon
- Dems Defend Drug Price Negotiation Bill Against GOP Outcry
- J&J Beats Tax Ruling Over Insurance Coverage Outside NJ
- Del. Justices Warned Not To Upend Fabric Of Disclosure Law
- Pursuing Wellness: A Focus On Firm Holistic Health Training
- THC Vaping Health Issues Warrant Safety Standards
- 3 Unanswered Tax Questions Facing M&A Attorneys
- Cannabis Delivery Framework Gets Mass. Commission's OK
- Hogan Lovells Adds Corporate Pro To Life Sciences Group
- Judging A Book
- Opioid MDL Judge Rejects J&J's Attack On Trial Format
- Abilify MDL Judge Boots 149 Claimants From Settlement
- Rochester Drug To Lead ADHD Generic Delay Class
- House Dems, Republicans Split On Cause Of Vaping Deaths
- Delaware Judge Misread Key Data, Stimwave Tells Fed. Circ.
- Ex-PetMed Exec Cuts Deal With SEC In Insider Trading Suit
- Doctor Can't Shake Convictions In $100M Referral Scheme
- DOJ Charges More Doctors In Appalachia Opioid Sweep
- Cardinal Health Board Wants Opioid Derivative Suit Axed
- Mass. Vape Ban Draws Ire Of State Pot Commissioner
- J&J Unit Escapes Suit Over Breast Implant Warnings
- Judge Jackson Reviews 'When Should Law Forgive?'
- Levi & Korsinsky, Bernstein Vie For Lead In Karyopharm Suits
- Fed. Circ. Rejects Injunction Bid In Orthodontic IP Row
- 11th Circ. Affirms Foreclosure Of Inyx Fraudster's Fla. Home
- China Biologic Committee To Weigh $4.59B Take-Private Bid
- Ex-FDA Director Says Agency Found J&J's Mesh Labels OK
- HHS Can Force Drug Prices In TV Ads, DC Circ. Hears
- Cannabis Atty Wants To Take Legalization Fight To Congress
- Disclosures Let Keryx Escape Kidney Drug Stock Suit
- Allergan Hit With Suit Over Recalled Breast Implants
- DOJ Goes After Philly Pharmacy For $1M In Bogus Billing
- Loestrin Judge Assigns Antitrust Homework Before Hearing
- Pursuing Wellness: Steps Toward A Supportive Firm Culture
- Wisconsin Lawmakers Introduce Medical Marijuana Bill
- 4 Biotech Firms Freshen Pipeline With IPOs Totaling $526M
- PTAB Should've Axed Cancer Detection Patent, Fed. Circ. Told
- Stats Show Cannabis Patents Are Underutilized
- J&J Beats Bias Suit From Woman Who Sought Exec Position
- CFIUS Risk Review Rules May Draw Attention To US Biotech
- J&J Escapes Fla. Pelvic Mesh Suit Also Aimed At Subsidiary
- Marketing By Vape Cos. 'Severely' Limited In LA Settlement
- Pradaxa User's Win Could Doom Thousands Of Other Suits
- Leading House Dem Wants Drug 'Hopping' Banned
- Allergan Investor Tries To Block $63B AbbVie Deal Over Info
- J&J's Litigation Bravado In Sharp Relief After Epic Opioid Trial
- Buyers Win Class Cert. In Blood Clot Drug Monopoly Suit
- J&J Gets Woman's $20M Mesh Award Trimmed To $15M
- Seven Firms To Steer 4 IPOs Raising $1.8B, Led By Peloton
- Pursuing Wellness: Mental Health Education As A Firm Priority
- Drugmaker Amag Under Pressure From Activist Investors
- GAO Report Illuminates Insurer Influence On Drug Discounts
- FDA Releases Proposed Rule On E-Cig Applications
- FDCA Doesn't Apply To Convicted NECC Workers, Judge Told
- Drug Suppliers Admit To UK Market Fixing, Watchdog Says
- Split DC Circ. Revives Howard U. Veterinarian's Firing Suit
- Jury's Task In Ohio Opioid MDL Trial Divides Drug Cos.
- Roundup, Essure Suits On A Collision Course, Judge Worries
- Cynosure Says Mass. Law Allows No 'Re-Do' Of False Ad Suit
- DOJ Allowed Into 7th Circ. Arguments On Syringe Price-Fixing
- Dem, GOP Lawmakers Ask FDA To Clear Path For CBD Retail
- J&J, Expert Debate If Asbestos In Talc Is 'Urban Legend'
- Pharmacy, PE Fund Ink $21M Deal To End FCA Kickback Suit
- Suboxone Maker's 'Gross Manipulation' Prompts $3M Fee Bid
- TridentUSA's $9.5M Medicare Scheme Settlement Gets OK
- Walgreens Settles Out Of 1-800 Contacts Antitrust Suit
- Purdue Files Ch. 11 Suit Seeking Stay Of Opioid Litigation
- Medical Device Co. Escapes Sabotage Suit Against Subsidiary
- Ex-Pharmacy Head Gets 33 Months In Misdosed Drugs Case
- Pursuing Wellness: A Firm's Work With Mental Health Experts
- House Democrats Unveil Drug Pricing Bill Opposed By GOP
- Rite Aid Gets Claims Trimmed In Deceptive Labeling Suit
- Searching For A Legal Pathway For CBD Products
- Purdue Loses Bid To Toss Mass. Suit Amid Ch. 11 Stay Fight
- ERISA Suit Over DST's 401(k) Plan Management Is Trimmed
- AbbVie Dodges Suit Over $100M Stock Drop
- FDA Launches Criminal Probe Into Vaping Deaths, Illnesses
- Ginkgo Lands $290M Cell Programming-Focused Series E
- Insys Ch. 11 Sale Of Controversial Drug OK'd With New Limits
- Woman's J&J Talc Bottle Contained Asbestos, Expert Says
- J&J Talc Supplier Given Time To Negotiate Insurance Deal
- Pa. Judge Questions 'Economics' Of Endo Antitrust Claims
- Skin Treatment Developer Can Use Lender Cash In Ch. 11
- Novartis Halts Zantac Distribution, Citing Impurities
- Fed. Circ. Refuses To Add Time To Intra-Cellular Patent Term
- TridentUSA Ch. 11 Plan Wins Court Approval
- Ark. Wants 'Biased' Judge Tossed From All State Cases
- W. Va. Hits J&J, Ethicon With Pelvic Mesh Suit
- Retina Drug Co. Can't End Claims It Misled Investors
- Pursuing Wellness: When A Firm Brings Counseling On Site
- Skadden-Led Envista Tops 2 Health Care IPOs Totaling $764M
- Outsourcing Facilities Face Rising Drug Compounding Risks
- Attys Seek $5M Award In AbbVie $16.7M Inversion Settlement
- Opioid 'Negotiation Class' Justifies DQ Bid, Distributors Say
- Inyx Fraudster's Wife Appeals Foreclosure By Deutsche Bank
- Bausch & Lomb Inks $10M Deal In Contact Lens Price-Fix Suit
- White House Dem Hopefuls Raise Pharma Deal Worries
- ITC Halts Dumping Probe Of Mexican Thermoplastic Sheets
- Attys Say SEC Can't Tie Firm To Sham PixarBio Merger
- Mintz Adds Ex-Cooley Life Sciences Trademark Pro In NY
- Foreign Patentees, Heed Fed. Circ. Jurisdiction Ruling
- Pharma Giants Can't Shake Ariz. Hospital's Opioid RICO Suit
- Purdue Says 'Lives, Dollars' At Stake In Bankruptcy Case
- Couple Stole Key Research From Hospital, Feds Say
- McConnell Wants CBD Enforcement Guidelines, Now
- Fed. Circ. Must Rethink Upholding Cancer Drug IP, Zydus Says
- Pa. Jury Urged To Punish J&J For Pushing Risperdal On Kids
- Pursuing Wellness: Inside A Firm Meditation Program
- Merck Trade Secret Suit A Ploy To Aid Patent Case, Pfizer Says
- 2 Fed. Circ. Decisions May Signal Pro-Patentee Swing
- 5th Circ. Says Noncompete Fight Doesn't Belong In Texas
- Clinical Stage Biopharma Co. Sienna Hits Ch. 11 In Del.
- Weil Was Upfront About Repping Insys In Ch. 11, Atty Says
- 4 Key Takeaways As Opioid MDL Distributors Seek Judge's DQ
- Fla. House Can Wade Into Medical Pot Law Case, Panel Says
- Kite Pharma Hit With Patent Suit Over Cancer Drug
- PTAB Says Mass. Biotech's Milk Patent Ineligible For Review
- Scientist Tells Calif. Court J&J Mesh Doesn't Degrade
- Top 5 Modern Tax Challenges For Digital Health Companies
- Generic Cos. Pan 'Irrelevant' Doc Demands In Price-Fix Case
- Investors Say Cancer Drug Co. Hyped Up Trial Results
- PTAB Rejects Stryker's Challenge To Medical Suture Patent
- Sanofi Faces 1st US Suit Over Likely Carcinogen In Zantac
- Pfizer's Tax Interest Row Belongs In Claims Court: 2nd Circ.
- Early Sampling Of Electronic Info Is Underutilized In Discovery
- Split Fed. Circ. Upholds Term Adjustment For Antibody Patent
- Dissent Exposes Flaws In Fed. Circ. ANDA Patent Holding
- Momenta, Sandoz Push For Sanctions In Blood Clot Drug Suit
- J&J Talc Supplier's $7.2M Deal With Insurers Faces Pushback
- Sentry Data, CVS Reach Deal In Antitrust Fight
- Opioid MDL Cos. Accused Of 'Inventing' Comments By Judge
- 3 Firms Guide Near-$2B Deal For Alder BioPharmaceuticals
- Court Is Wrong Place For Monopoly Case, E-Scrip Co. Says
- Teva Wants Pa. Investor Suit To Join Others In Conn.
- Jury Left In Dark On Key Trial Issue, Antrim Tells 7th Circ.
- Purdue Pharma Seeks To Halt Opioid Suits With Ch. 11 Filing
- Opioid MDL Judge Deserves DQ For Bias, Distributors Say
- Jones Day Attys 'Very Much Regret' Grand Jury Redaction Slip
- Cos. Reach $9.5M Deal For Selling Non-FDA Cleared Devices
- High Prices Are Side Effect Of AbbVie-Allergan Deal, Feds Told
- Taxation With Representation: Wachtell, McDermott, Latham
- DOJ Asks To Argue In Health Cos.' Syringe Price-Fix Appeal
- 3rd Circ. Sends J&J Remicade Antitrust Fight to Arbitration
- 6 Firms To Steer Health Care, Tech IPOs Set To Raise $1.5B
- AbbVie Investors Ask To Drop Ill. Humira Kickback Suit
- Rakoff Scolds Gov't, Sets Life Spine Kickback Trial For 2020
- DEA Blocking Medical Cannabis Research Licenses, Lab Says
- Frayed Family IP Royalty Biz Gets Chancery Appraisal Look
- Purdue's Sacklers Shifted $1B Amid Opioid Fight, NY AG Says
- Drug Pricing Site Can't Escape Pharmacy Groups' Blacklists
- J&J Trims Claims From Colo. Man's Hernia Mesh Suit
- Rising Star: Quinn Emanuel's Matthew Robson
- Endo Says Drop Direct Buyers' Cert. Bid In Pay For Delay Row
- Goodwin, Latham Steer Life Sciences IPOs Totaling $244.5M
- Meet The Attys Leading The Opioid MDL 'Negotiation Class'
- U. Of Minn. Urges Supreme Court To Consider PTAB Immunity
- Quest Cleared In Cedars-Sinai Trade Secrets Row
- The Factors Courts Consider In Deposition Location Disputes
- $10M Award In J&J, Colgate Talc Trial Must Go, Judge Told
- Vectura Gets $10M Added To $90M Inhaler IP Award
- Purdue Bankruptcy May Leave State AGs Out In The Cold
- Pradaxa User's $542K Jury Win Upheld, Despite 'Close Call'
- 3rd Circ. Says No Hearing Guarantee For FCA Suit Dismissal
- PTAB Says Not Unfair To Review Amgen Chemo Patents
- CBD Cos. Fall Short On Testing And Labeling, Watchdog Says
- Patent Bill Would 'Do More Harm Than Good,' Lawmakers Told
- NY Rep. Collins Denies Feds' Redrawn Insider Trading Case
- 3rd Circ. Revives State-Law Fraud Claims By Merck Opt-Outs
- Vanda Pharma Investor Accuses Brass Of Off-Label Marketing
- Biopharma Co. Investors Allege Voting Rule Fouls In Del. Suit
- Rising Star: Greenberg Traurig's Fang Xie
- What To Consider Before Filing For A Rule 57 Speedy Hearing
- Creative Ways To Challenge Master Complaints In MDLs
- Simpson Thacher Steers Genomics' $390M Upsized IPO
- Skadden-Led SmileDirectClub Prices $1.3B IPO Above Range
- PTAB Weighs Whether Cattle Breeding Patent Is Obvious
- Jones Day Needs Mea Culpa To Avoid Grand Jury Flub Fallout
- 6th Circ. Won't Reinstate DQ'd BakerHostetler In Opioid MDL
- J&J Can't Duck Fla. Pelvic Mesh Suit Over Expert Evidence
- Reed Smith's LA Office Adds 2 Arent Fox Employment Alums
- Stymied By Imerys Ch. 11, Talc Case Returns To Lower Court
- Bull Semen Sorting Co. Wins $8.5M From Rival In IP Trial
- China Spares 16 US Goods From Duties Ahead Of Talks
- Opioid MDL 'Negotiation Class' Wins Approval
- Swiss Biotech Acquires Maker Of Celiac Drug Nearing Trials
- Rising Star: Fenwick & West's Robert Counihan
- Purdue To Settle Thousands Of Opioid Suits, File Bankruptcy
- Biogen Tells 1st Circ. Firing Was Unrelated To Mental Health
- Jones Day Faces Sanctions Threat After Redaction Flub
- Investors Say Suit Over Philip Morris E-Cig Sales Must Go On
- Reviewing Recent FDA Activity In Bulk Drugs Lists
- White House Prepares To Ban Flavored E-Cigs
- J&J Hit With $37.3M Verdict In NJ Talc Case
- Jones Day Botches Grand Jury Redaction In Attack On DOJ
- FDA Faces Free Speech Issues With Juul Warnings
- Canadian Cannabis Biz Hit With Investor Suit Over $143M IPO
- J&J Says Science Backs Its Talc At Opening Of Calif. Retrial
- Organon Whistleblowers Acted As Law Expects, 1st Circ. Says
- Fed. Circ. OKs Ax Of Surgical IP At Heart Of $10M Settlement
- Rising Star: Butler Snow's Alyson Jones
- Stem Cell Biz Facing Fraud Claims Declares Bankruptcy
- Weil Downplayed Atty Conflict, Convicted Insys Exec Says
- Ex-NHL Owner Accuses SEC Of Icing Document Request
- Simpson Thacher-Led Genomics Co. Ups IPO Target To $342M
- Baxter International To Pay Up To $230M For Cheetah Medical
- Dr. Reddy's, Hospira Want Full Fed. Circ. To Redo Lilly IP Win
- Why I Became A Lawyer: Expanding The Meaning Of Diversity
- Purdue, Opioid Distributors Can't Dodge RICO Claims In MDL
- Del. Judge 'Unlikely' To Halt True Health Medicare Payments
- J&J Wants Mistrial For Struck Talc Trial Closing Arguments
- Mallinckrodt To Sell BioVectra To HIG For Up To $250M
- J&J Hid Asbestos In Talc, Woman Tells 2nd Jury After Mistrial
- Feds Ask To Delay Proposed Subsys Sale
- Fed. Circ. Won't Rehear OxyContin Patent Claims
- 13 States Urge 6th Circ. To Block Ohio Opioid Bellwether
- Rising Star: Arnold & Porter's Eric Rothman
- 9th Circ. Revives Decade-Old Medicare Fraud Qui Tam Suit
- $10M Award May 'Raise Stakes' For Firing Mass. Profs
- Genentech Gets Taiwanese Co. To Abandon Biosimilars
- Datadog Leads IPO Flurry Expected To Raise $729M Combined
- State Law Issues The Court Missed In Cancer Drug Trial Case
- Juul Illegally Marketed E-Cigs As Safe To Youths, FDA Says
- Law360 Names Top Attorneys Under 40
- Fed. Circ. Clouds Landscape For Medical Treatment Patents
- Stryker Must Pay For IP Marking Failure, Acantha Says
- Biopharma Co. Regulus Dodges Stock Suit Over Drug Trials
- Exec Accused As Part Of $1.2B Fraud Scam Enters Guilty Plea
- Edibles Co. Sees TM Claims Tossed Over Pot's Illegal Status
- Deals Rumor Mill: LGC, G4S, Symantec
- Lone Star Laterals: Skadden, Haynes and Boone, Locke Lord
- 9 Firms To Guide 6 IPOs Eyeing Nearly $2.2B To Start Sept.
- Zicam Maker Hit With Patent Suit Over Nasal Spray Formula
- Womble Bond Boosts Product Liability Group In Atlanta
- Mallinckrodt Pays $24M To Exit Opioid MDL Bellwethers
- Japan's Sumitomo Dainippon Mulls $3B Roivant Drug Buy
- Why Opioid Suits Avoid GCs — And Why That Could Change
- Discovery Counsel Vital In All Phases Of Mass Tort Litigation
- Fed. Circ. Probes If Galderma Bound By Statements To PTAB
- Alcor Wins Bid To Overturn $6.5M Blood Testing IP Verdict
- 4 Key Takeaways As Ohio AG Fires Torpedo At Opioid MDL
- CVS-Aetna Review Ends In Parting Shots & Punctuation!
- Fed. Circ. Backs Genentech's Win On Phigenix Cancer Patent
- State Immunity Isn't Free-Rein On Venue, Fed. Circ. Says
- Pa. Judge Questions Standing For Health Fund In Opioid Case
- Mylan Tells Fed. Circ. That Sanofi Insulin Patents Not Special
- Mallinckrodt Pays $15M In 'Wine And Dine' FCA Case
- Ex-Aegerion CEO Says Ch. 11 Plan Vote Is Unfair
- European Investors Lead Medical Co.'s $44M Funding Round
- How The Wayback Machine Can Strengthen Your Case
- Colgate Tries To Narrow ERISA Suit Over Lump-Sum Payouts
- Bellus Health Raises $70M In Upsized Stateside IPO
- Pay-For-Delay Bill Goes Too Far, Conservative Org. Says
- J&J Wouldn't Risk 'Golden Egg' With Talc Warning, Jury Told
- Cedars-Sinai Doc Toiled 15 Years To Invent IBS Test, Jury Told
- 1st Circ. Weighs Payout For Fired Abiomed Exec
- Whether Opioid Crisis Is 'Public Nuisance' Up To Jury: Judge
- Pharmaceutical Cos., Shipping Co. Settle Kickbacks Suit
- J&J Asks Court To Toss 401(k) Savers' Suit Over Stock-Drop
- J&J Must Face Upcoming Risperdal Punitive Damages Trial
- Gilead Says HIV 'No Generic' Suit Is Baseless
- Stryker To Buy Pair Of Medical Tech Cos. For Up To $500M
- Fed. Circ. Judge 'Bewildered' Teva Got $235M Verdict Nixed
- Former FDA Head Can Testify In Sanofi Hair Loss Trial
- Weil Atty's Closing Argument Struck As J&J Talc Trial Wraps
- Pharma Co. Gets False Ad Suit Over Anesthetic Drug Trimmed
- CVS-Aetna Merger Cleared After Unprecedented Court Battle
- Skadden Steers Danaher Dental Unit's Potential $600M IPO
- Mississippi's Mental Health System Violates ADA, Judge Says
- Risks To Avoid When Conducting Virtual Clinical Trials
- Mail-Order Fecal Analysis Startup Files For Bankruptcy
- Fed. Circ. Muddies Waters On Method-Of-Treatment Patents
- Deals Rumor Mill: Poshmark, Lindsay Goldberg, Selecta
- Draft Civil Procedure Jurisdictional Rule Needs A Tweak
- Vensana Capital Wraps Up Inaugural Fund With $225M In Tow
- Opioid MDL Jury Will Weigh 'Complete Failures' By Drug Cos.
- Practicality Key In Suboxone Class Cert. Bid, Judge Suggests
- Lack Of Asbestos 'Biomarkers' Looms Over J&J Talc Trial
- CVS Mad About Findings, Not Discovery Pace, Sentry Says
- Quest Diagnostics Can't Use High Court To Evade TCPA Case
- Stryker Gets Ax Of Ex-NFL Player's Pain Pump Claims
- Monsanto Says LA County's PCB Suit Filed Too Late
- Fed. Circ. Pulls Contested Line In Its Sandoz Biosimilar Ruling
- Pharma Deal Made Monopoly For Diabetes Drug, Buyer Says
- Vertex Sets Sights On Diabetes Cure With $950M Semma Buy
- 5 Health Care IPOs Could Total $682M, Led By Genomics Biz
- Pharma Group Fights Injunction For Blacklisted Pricing Site
- Compliance Monitor May Help With CFIUS Approval
- Skadden-Led Orthodontics Biz Launches Potential $1.2B IPO
- Bankrupt Insys Plans Fentanyl Spray Sale To Competitor